Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Voyager Therapeutics, Inc. (VYGR)

5.57   -0.37 (-6.23%) 09-24 14:35
Open: 6.04 Pre. Close: 5.94
High: 6.19 Low: 5.365
Volume: 169,162 Market Cap: 215(M)
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.2 - 6.24 6.24 - 6.28
Low: 5.28 - 5.31 5.31 - 5.35
Close: 5.5 - 5.56 5.56 - 5.63

Technical analysis

as of: 2022-09-23 4:28:34 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 7.66     One year: 8.52
Support: Support1: 5.36    Support2: 4.46
Resistance: Resistance1: 6.56    Resistance2: 7.3
Pivot: 6.47
Moving Average: MA(5): 5.95     MA(20): 6.34
MA(100): 6.17     MA(250): 5.24
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 16.6     %D(3): 22.6
RSI: RSI(14): 37.1
52-week: High: 10.6  Low: 2.46
Average Vol(K): 3-Month: 205 (K)  10-Days: 127 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ VYGR ] has closed below the lower bollinger band by 4.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ VYGR ] is to continue within current trading range. Bollinger Bands are 3.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 22 Sep 2022
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - EIN News

Wed, 21 Sep 2022
Voyager Therapeutics : Statement of Changes in Beneficial Ownership - Form 4 - Marketscreener.com

Thu, 15 Sep 2022
7 Top-Rated Biotech Stocks to Buy for Q4 - InvestorPlace

Wed, 07 Sep 2022
Voyager Therapeutics Names Peter Pfreundschuh Chief Financial Officer >VYGR - MarketWatch

Fri, 26 Aug 2022
Rock Ventures Iii L.P. Third Sells 149972 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock - MarketBeat

Thu, 04 Aug 2022
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 39 (M)
Shares Float 20 (M)
% Held by Insiders 14.2 (%)
% Held by Institutions 60.1 (%)
Shares Short 1,190 (K)
Shares Short P.Month 941 (K)

Stock Financials

EPS -1.88
EPS Est Next Qtl -0.78
EPS Est This Year -2.87
EPS Est Next Year -2.76
Book Value (p.s.) 1.55
Profit Margin (%) -193.5
Operating Margin (%) -194.6
Return on Assets (ttm) -19
Return on Equity (ttm) -70.2
Qtrly Rev. Growth -47.5
Gross Profit (p.s.) -0.95
Sales Per Share 0.8
EBITDA (p.s.) -1.39
Qtrly Earnings Growth 0
Operating Cash Flow 6 (M)
Levered Free Cash Flow 53 (M)

Stock Valuations

PE Ratio -2.98
PEG Ratio 0
Price to Book value 3.57
Price to Sales 6.96
Price to Cash Flow 33.48

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.